Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: Unexpected incidence of hypersensitivity reactions

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 369-375

  Lin, Nancy U ^a   Parker, Leroy M ^a   Come, Steven E ^b   Burstein, Harold J ^a   Haldoupis, Margaret ^a   Ryabin, Nicole ^a   Gelman, Rebecca ^a   Winer, Eric P ^a   Shulman, Lawrence N ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

CT 2103; Metastatic breast cancer; Taxanes; Xyotax

Indexed keywords

PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYGLUTAMIC ACID;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POLYGLUTAMIC ACID; TAXOIDS;

EID: 34250612643     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9034-y     Document Type: Article

References (23)

1. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18(4):724-733
2. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J et al (1995) Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13(10):2575-2581
3. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14(6):1858-1867
4. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European organization for research and treatment of cancer. J Clin Oncol 13(2):314-322
5. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18(6):1212-1219
6. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17(8):2341-2354
7. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019-6026
8. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22(11):2061-2068
9. O'Shaughnessy J, Tjulandin S, Davidson N, Shaw H, Desai N, Hawkins M, Gradishar WJ (2003) ABI-007 (Abraxane), a nanoparticle albumin-bound (NAB) paclitaxel demonstrates superior efficacy vs. Taxol in MBC: a phase III trial. In: San Antonio breast cancer symposium
10. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Naughton M, Norton L, Winer E, Hudis C (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22(14S): abstract 512
11. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588-592
12. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542-5551
13. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47(9):2486-2493
14. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, Young CW (1986) Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70(5):605-607
15. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC, Swaminathan S, Trump DL (1987) Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 71(12):1179-1184
16. Robson L, Verrill M, Lind M, Simmons P, Perren T, Coombes C, Earl H, Calvert H, Campbell M, Bolton M (2003) A phase 2 study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:42
17. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN, Davidson NE (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. In: American Society of Clinical Oncology 41st annual meeting
18. Bonomi P, Paz-Ares L, Langer C (2005) Xyotax vs docetaxel for the second line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III trial. Lung Cancer 29(Suppl 2):S35
19. Langer CJ, Socinski MA, Ross H, O'Byrne KJ (2005) Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for PS2 patients with chemotherapy-naive advanced non-small cell lung cancer: a phase III study. J Clin Oncol 23(16S):623s
20. Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D (2004) Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22(22):4523-4531
21. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17(4):1141
22. Schiavetti A, Varrasso G, Maurizi P, Castello MA (1999) Hypersensitivity to carboplatin in children. Med Pediatr Oncol 32(3):183-185
23. Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, Giannopoulos A, Karatzas G, Giannikos L, Sfikakis PP (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61(2):129-133